Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab

HELSINKI, July 13, 2021 /PRNewswire/ -- Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has submitted a clinical trial application (CTA) to the German Regulatory Agency, The Paul Ehrlich...

from PR Newswire: https://ift.tt/3xBWrov